Page 43 - Read Online

Hodge J, Soong R, Goh BC. Response to a novel multitargeted carcinoma. Am J Pathol 201610.1016/j.ajpath.2015.11.020.
tyrosine kinase inhibitor pazopanib in metastatic Merkel cell 142. Panelos J, Batistatou A, Paglierani M, Zioga A, Maio V, Santi R,
carcinoma. J Clin Oncol 2009;27:e97-100. Pimpinelli N, De Giorgi V, Santucci M, Massi D. Expression of
126. Hafner C, Houben R, Baeurle A, Ritter C, Schrama D, Landthaler Notch-1 and alteration of the E-cadherin/beta-catenin cell adhesion
M, Becker JC. Activation of the PI3K/AKT pathway in Merkel cell complex are observed in primary cutaneous neuroendocrine
carcinoma. PLoS One 2012;7:e31255. carcinoma (Merkel cell carcinoma). Mod Pathol 2009;22:959-68.
127. Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, 143. Viola D, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A,
Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman Lorusso L, Cappagli V, Pieruzzi L, Giani C, Sabini E, Passannati
J, Ryan DP, Borger DR, Bhan AK, Hoang MP, Iafrate AJ, Cusack P, Puleo L, Matrone A, Pontillo-Contillo B, Battaglia V, Mazzeo
JC, Engelman JA, Dias-Santagata D. Activation of PI3K signaling in S, Vitti P, Elisei R. Treatment of advanced thyroid cancer with
Merkel cell carcinoma. Clin Cancer Res 2012;18:1227-36. targeted therapies: ten years of experience. Endocr Relat Cancer
128. Samimi M, Touze A, Laude H, Le Bidre E, Arnold F, Carpentier 2016;23:R185-205.
A, Gardair C, Carlotti A, Maubec E, Dupin N, Aubin F, Avril MF, 144. Elisei R, Pinchera A. Advances in the follow-up of differentiated or
Rozenberg F, Avenel-Audran M, Guyetant S, Lorette G, Machet L, medullary thyroid cancer. Nat Rev Endocrinol 2012;8:466-75.
Coursaget P. Vitamin D deficiency is associated with greater tumor 145. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore
size and poorer outcome in Merkel cell carcinoma patients. J Eur TC, Howe JR, Moley JF, Goodfellow P, Wells SA, Jr. Mutations in
Acad Dermatol Venereol 2014;28:298-308. the RET proto-oncogene are associated with MEN 2A and FMTC.
129. Batinica M, Akgul B, Silling S, Mauch C, Zigrino P. Correlation of Hum Mol Genet 1993;2:851-6.
Merkel cell polyomavirus positivity with PDGFRalpha mutations 146. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner
and survivin expression in Merkel cell carcinoma. J Dermatol Sci E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius
2015;79:43-9. H, Tunnacliffe A, Ponder BAJ. Germ-line mutations of the RET
130. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik proto-oncogene in multiple endocrine neoplasia type 2A. Nature
A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S. 1993;363:458-60.
Phase I and pharmacokinetic study of YM155, a small-molecule 147. Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S,
inhibitor of survivin. J Clin Oncol 2008;26:5198-203. Cirello V, Bottici V, Marconcini G, Rosa PM, Borrello MG, Basolo
131. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, Xu F, Ugolini C, Materazzi G, Pinchera A, Elisei R. Evidence of a low
H, Nayar SK, Wang TS, Sidransky D, Anders RA, Topalian SL, Taube prevalence of RAS mutations in a large medullary thyroid cancer
JM. PD-L1 expression in the Merkel cell carcinoma microenvironment: series. Thyroid 2013;23:50-7.
association with inflammation, Merkel cell polyomavirus and overall 148. Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts
survival. Cancer Immunol Res 2013;1:54-63. NJ, Bhan S, Ho AS, Khan Z, Bishop J, Westra WH, Wood LD,
132. Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, Hruban RH, Tufano RP, Robinson B, Dralle H, Toledo SP, Toledo
LaBelle A, Zukerberg L, Lambert JM, Lutz RJ. Lorvotuzumab RA, Morris LG, Ghossein RA, Fagin JA, Chan TA, Velculescu VE,
mertansine, a CD56-targeting antibody-drug conjugate with potent Vogelstein B, Kinzler KW, Papadopoulos N, Nelkin BD, Ball DW.
antitumor activity against small cell lung cancer in human xenograft Exomic sequencing of medullary thyroid cancer reveals dominant
models. MAbs 2014;6:556-66. and mutually exclusive oncogenic mutations in RET and RAS. J
133. Veija T, Sarhadi VK, Koljonen V, Bohling T, Knuutila S. Hotspot Clin Endocrinol Metab 2013;98:E364-9.
mutations in polyomavirus positive and negative Merkel cell 149. Schneider TC, de Wit D, Links TP, van Erp NP, van der Hoeven JJ,
carcinomas. Cancer Genet 2016;209:30-5. Gelderblom H, van Wezel T, van Eijk R, Morreau H, Guchelaar HJ,
134. Cohen PR, Tomson BN, Elkin SK, Marchlik E, Carter JL, Kurzrock Kapiteijn E. Beneficial Effects of the mTOR Inhibitor Everolimus in
R. Genomic portfolio of Merkel cell carcinoma as determined Patients with Advanced Medullary Thyroid Carcinoma: Subgroup
by comprehensive genomic profiling: implications for targeted Results of a Phase II Trial. Int J Endocrinol 2015;2015:348124.
therapeutics. Oncotarget 201610.18632/oncotarget.8032. 150. Lim SM, Chang H, Yoon MJ, Hong YK, Kim H, Chung WY, Park
135. Cimino PJ, Robirds DH, Tripp SR, Pfeifer JD, Abel HJ, Duncavage CS, Nam KH, Kang SW, Kim MK, Kim SB, Lee SH, Kim HG, Na,
EJ. Retinoblastoma gene mutations detected by whole exome II, Kim YS, Choi MY, Kim JG, Park KU, Yun HJ, Kim JH, Cho
sequencing of Merkel cell carcinoma. Mod Pathol 2014;27:1073-87. BC. A multicenter, phase II trial of everolimus in locally advanced
136. Graves CA, Jones A, Reynolds J, Stuart J, Pirisi L, Botrous P, or metastatic thyroid cancer of all histologic subtypes. Ann Oncol
Wells J. Neuroendocrine Merkel cell carcinoma is associated with 2013;24:3089-94.
mutations in key DNA repair, epigenetic and apoptosis pathways: 151. Lin SF, Huang YY, Lin JD, Chou TC, Hsueh C, Wong RJ. Utility of
a case-based study using targeted massively parallel sequencing. a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.
Neuroendocrinology 2015;101:112-9. PLoS One 2012;7:e46726.
137. Harms PW, Collie AM, Hovelson DH, Cani AK, Verhaegen ME, 152. Juweid ME, Hajjar G, Stein R, Sharkey RM, Herskovic T, Swayne LC,
Patel RM, Fullen DR, Omata K, Dlugosz AA, Tomlins SA, Billings Suleiman S, Pereira M, Rubin AD, Goldenberg DM. Initial experience
SD. Next generation sequencing of Cytokeratin 20-negative Merkel with high-dose radioimmunotherapy of metastatic medullary thyroid
cell carcinoma reveals ultraviolet-signature mutations and recurrent cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen
TP53 and RB1 inactivation. Mod Pathol 2016;29:240-8. MAb and AHSCR. J Nucl Med 2000;41:93-103.
138. Tilling T, Moll I. Which are the cells of origin in merkel cell 153. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG,
carcinoma? J Skin Cancer 2012;2012:680410. Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg
139. McCardle TW, Sondak VK, Zager J, Messina JL. Merkel cell MJ, Sun YN, Juan T, Stepan DE, Sherman SI. Phase II study of
carcinoma: pathologic findings and prognostic factors. Curr Probl safety and efficacy of motesanib in patients with progressive or
Cancer 2010;34:47-64. symptomatic, advanced or metastatic medullary thyroid cancer. J
140. Zur Hausen A, Rennspiess D, Winnepenninckx V, Speel EJ, Kurz Clin Oncol 2009;27:3794-801.
AK. Early B-cell differentiation in Merkel cell carcinomas: clues to 154. Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin
cellular ancestry. Cancer Res 2013;73:4982-7. S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK,
141. Abraham KJ, Zhang X, Vidal R, Pare GC, Feilotter HE, Tron Bycott P, Cohen EE. Treatment of advanced thyroid cancer with
VA. Roles for miR-375 in neuroendocrine differentiation and axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic
tumor suppression via Notch pathway suppression in Merkel cell and quality-of-life assessments. Cancer 2014;120:2694-703.
292
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 17, 2016 ¦